Adult immunization. Summary of the National Vaccine Advisory Committee Report

Fedson, David S.

doi:10.1001/jama.272.14.1133

Cited by 92 publications

(43 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, for vaccination in the 50-64 year age group, the cost per added year of healthy life would be below that of well-established preventive measures such as colon cancer screening 9 . Finally, lowering the age of universal immunization would harmonize the influenza and pneumococcal schedules, mitigating one of the major barriers cited by the National Vaccine Advisory Committee 17 . Universal vaccination beginning at age 50 years would decrease the need to identify chronic conditions and could enhance the use of standing orders for PPV delivery 18,19 .…”

Section: Discussionmentioning

confidence: 99%

Pneumococcal Vaccination in General Internal Medicine Practice: Current Practice and Future Possibilities

Kempe

Hurley

Stokley³

et al. 2008

J GEN INTERN MED

View full text Add to dashboard Cite

BACKGROUND: Pneumococcal vaccine (PPV) is recommended for adults ≥65 years and those with chronic illness, but there are potential advantages of universal vaccination of adults age 50-64 years. OBJECTIVE:To assess reported (1) recommendations and administration practices of general internists for PPV, (2) barriers to vaccination, and (3) willingness to expand vaccination to all adults ≥50 years.METHODS: National survey of general internists representative of the American College of Physicians. RESULTS:Response rate was 74% (N=326). Although 99% reported giving PPV, less than 20% used a computerized database to identify eligible patients by age or diagnoses and only 6% recalled patients. Major barriers included acute problems taking precedence over preventive care (39%), difficulty determining vaccination history (30%), not thinking of it/not a priority (20%), and inadequate reimbursement for vaccine (19%). If ACIP expanded recommendations, 60% would definitely and 37% would probably institute this change.CONCLUSIONS: Most general internists reported giving PPV, but delivery was hindered by competing demands, lack of systems to identify patients needing vaccination, and reimbursement issues. Barriers might be decreased by a policy of universal vaccination of adults ≥50 years, and the majority of physicians reported they would follow such a recommendation if it were made.

show abstract

Section: Discussionmentioning

confidence: 99%

Pneumococcal Vaccination in General Internal Medicine Practice: Current Practice and Future Possibilities

Kempe

Hurley

Stokley³

et al. 2008

J GEN INTERN MED

View full text Add to dashboard Cite

show abstract

“…A vacina deve ser aplicada pelo menos duas semanas antes da esplenectomia. O intervalo entre o uso da vacina e de terapia imunossupressora deve ser o mais longo possível (72) .…”

Section: Vacinaçõesunclassified

Fatores de risco e medidas profiláticas nas pneumonias adquiridas na comunidade

Gomes

2001

J. Pneumologia

View full text Add to dashboard Cite

show abstract

“…Several factors have been proposed as accounting for the poor vaccination rates in adults, like the limited perception of health care providers and the general public that vaccinations are important to prevent diseases, or doubts in the doctor`s and patient`s minds about the efficacy and safety of the vaccines used for adults [18].…”

Section: Resultsmentioning

confidence: 99%

Influenza vaccination in Austria, 1982–2003

Kunze

Groman

Böhm

et al. 2007

Wien Med Wochenschr

View full text Add to dashboard Cite

Since the past decade influenza vaccination is becoming an increasingly important aspect of public health programs. In the early 1990s independent investigators began to gather information on the comparative use of influenza vaccine in developed countries. The annual level of influenza vaccine distributed in each country was calculated as the number of doses distributed per 1000 total resident population. During the first period of research in 18 developed countries influenza vaccine was widely underused. From 1980 to 1992 the annual vaccination rates increased in most of the 18 countries. But Austria (Switzerland and Finland) showed little change (20 doses/1000 in 1982 and 23 doses in 1992). When in 1992-1995 four new countries were included, doses increased slightly in Austria, too, to about 52 doses/1000 in 1995, but the country still belonged to the low-use countries compared to Spain 160 doses/1000, although vaccination was recommended for all elderly people <65 years and persons with high-risk medical conditions. Self-payment was usual, and there was no reimbursement within the national or social health insurance schemes. From 1996 (77 doses/1000), to 2000 (118 doses/1000) and 2003 (127 doses/1000), vaccination increased slightly, but Austria remained one of the lowest three Western European countries reported, together with Sweden (127) and Norway (102). Possible reasons for the low usage in Austria may be the following: people mistake influenza for an influenza-like illness, a lack of effective social marketing, costs are not taken over by social or private insurance and discordance in the Austrian medical fraternity about the importance of vaccination. Especially in view of a possible new influenza pandemic, public awareness of the importance of vaccination must increase.

show abstract

Adult immunization. Summary of the National Vaccine Advisory Committee Report

Cited by 92 publications

References 18 publications

Pneumococcal Vaccination in General Internal Medicine Practice: Current Practice and Future Possibilities

Pneumococcal Vaccination in General Internal Medicine Practice: Current Practice and Future Possibilities

Fatores de risco e medidas profiláticas nas pneumonias adquiridas na comunidade

Influenza vaccination in Austria, 1982–2003

Contact Info

Product

Resources

About